진양제약
Financials
Valuation Metrics
진양제약's Market Cap is ₩486B. At end of 2025 it was ₩711B. Ranked #1732 of 2,410 in KR market (top 72%), #1049 of 1,631 on KOSDAQ (top 64%), #185 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 80%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 48.62B KRW | KR#1,732/2,410 Sec#185/231 |
| Revenue | 124.61B KRW | KR#1,289/2,410 Sec#79/231 |
| Net Income | 22.80B KRW | KR#659/2,410 Sec#44/231 |
| Total Assets | 274.42B KRW | KR#1,086/2,410 Sec#73/231 |
| Net Assets | 162.16B KRW | KR#1,085/2,410 Sec#76/231 |
| Employees | 213 | KR#1,049/2,410 Sec#87/231 |
| Value | ||
| P/E | 2.13x | KR#92/2,410 Sec#4/231 |
| P/B | 0.30x | KR#400/2,410 Sec#14/231 |
| P/S | 0.39x | KR#802/2,410 Sec#27/231 |
| EV/EBITDA | 32.47x | KR#1,252/2,410 Sec#78/231 |
| FCF Yield | -0.37% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | 14.06% | KR#371/2,410 Sec#26/231 |
| ROA | 8.31% | KR#414/2,410 Sec#30/231 |
| Op. Margin | 3.04% | KR#1,246/2,410 Sec#89/231 |
| Revenue Growth | 4.23% | KR#1,238/2,410 Sec#124/231 |
| Earnings Growth | -20.66% | KR#934/2,410 Sec#58/231 |
| Financial Health | ||
| Debt Ratio | 69.23% | KR#1,206/2,410 Sec#147/231 |
| Total Debt | 75.57B KRW | KR#832/2,410 Sec#55/231 |
| FCF | -179.1M KRW | KR#1,230/2,410 Sec#94/231 |
| Cash | 1.12B KRW | KR#2,320/2,410 Sec#220/231 |
| Current Ratio | 0.52x | KR#2,122/2,410 Sec#205/231 |
| Net Debt/EBITDA | 19.64x | KR#1,368/2,410 Sec#98/231 |
| Dividend | ||
| Div. Yield | 4.41% | KR#405/2,410 Sec#14/231 |
| Div. Growth | 0.00% | KR—/2,410 Sec—/231 |
| Performance | ||
| 1Y Return | -36.88% | KR#1,627/2,410 Sec#132/231 |
| 1M Return | -13.46% | KR#1,571/2,410 Sec#157/231 |
| From 52W High | -39.65% | KR#738/2,410 Sec#50/231 |
| 1Y MDD | -38.65% | KR#528/2,410 Sec#37/231 |
| Trading | ||
| Volume | 15,537 shares | KR#1,503/2,410 Sec#151/231 |
| Trading Value | 53.3M KRW | KR#1,620/2,410 Sec#170/231 |
| Foreign Own. | 3.04% | KR#1,277/2,410 Sec#117/231 |
| Per Share | ||
| EPS | 1,613 KRW | KR#524/2,410 Sec#37/231 |
| BPS | 11,472 KRW | KR#903/2,410 Sec#62/231 |
Company Info
Jinyang Pharmaceutical, a mid-sized company, was established in 1971 for manufacturing and selling pharmaceuticals, converted to a corporation in 1978, and listed on KOSDAQ in 2000. It produces prescription and over-the-counter drugs, with a focus on the circulatory system segment, aiming for differentiation through new drug development from its generic-centric business structure. The company pursues substantial growth by strengthening marketing for its core circulatory products, investing in R&D, and developing new products. It is also preparing to launch new products through domestic and international patents and technology partnerships. Jinyang Pharmaceutical is headquartered in Seocho-gu, Seoul.